Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Company Overview - Innoviva was originally formed to manage royalty revenues from products developed with and licensed to GSK [1] - The company has evolved to create and drive shareholder value through three main components [1] Revenue Streams - The first component is the royalty business from two respiratory assets, Breo and Anoro, generating $250 million in gross royalty revenue last year [1] - The second component is the Specialty Therapeutics business, which delivered almost $120 million in U.S. sales last year and is expected to generate at least $150 million this year [2]